Coloplast's urology business takes growth leap after Covid-19 dive
Two years after Coloplast considered selling off its urology division, President and CFO at the company Anders Lonning-Skovgaard is happy they decided to keep and invest in the area, though the grounds for comparison this year were favorable.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
While Coloplast's business area Continence Care saw an organic growth of 5 percent in the financial year that just ended, where the Ostomy Care also grew with 6 percent, the medtech company's urology division skyrocketed with an organic growth of 19 percent in the same period, the company's states in its 2020/2021 financial full-year report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast expects organic growth of 7 percent next year
For subscribers
Coloplast could win big on Polish reimbursement changes
For subscribers
